Literature DB >> 7026595

Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone.

T L Woodard, G A Burghen, A E Kitabchi, J A Wilimas.   

Abstract

Because of a suspected association between the drug oxymetholone and abnormal glucose metabolism, we determined immunoreactive insulin (IRI) and plasma glucose during oral glucose tolerance testing in seven patients with aplastic anemia, six of whom received oxymetholone therapy. All patients receiving oxymetholone therapy had abnormal glucose and/or IRI values. This finding was independent of GH, cortisol, and glucagon. In one patient, glucose and IRI levels were normal before oxymetholone but became abnormally elevated after the use of this drug. Furthermore, normal glucose and IRI values were present in the single patient not receiving oxymetholone. Thus, a positive relationship was demonstrated between oxymetholone administration and the presence of glucose intolerance and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7026595     DOI: 10.1210/jcem-53-5-905

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  The relationships between testosterone, body composition, and insulin resistance: a lesson from a case of extreme hyperandrogenism.

Authors:  Elena Volpi; Steven A Lieberman; Dennis M Ferrer; Charles R Gilkison; Blake B Rasmussen; Manubai Nagamani; Randall J Urban
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

2.  Severe hyperglucagonaemia during treatment with oxymetholone.

Authors:  G Williams; M Ghatei; J Burrin; S Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-21

Review 3.  Body size regulation and insulin-like growth factor signaling.

Authors:  Seogang Hyun
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

Review 4.  Epidemiological and policy issues in the measurement of the long term health effects of anabolic-androgenic steroids.

Authors:  C E Yesalis; J E Wright; M S Bahrke
Journal:  Sports Med       Date:  1989-09       Impact factor: 11.136

5.  Hyperandrogenism, hyperinsulinism and polycystic ovarian disease.

Authors:  R Pasquali; S Venturoli
Journal:  J Endocrinol Invest       Date:  1986-12       Impact factor: 4.256

6.  Reduction of insulin resistance after correction of nonneoplastic ovarian virilization.

Authors:  M Baldini; E Semprini; A Orsatti; G Viale; L Cantalamessa
Journal:  J Endocrinol Invest       Date:  1993-04       Impact factor: 4.256

7.  Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1.

Authors:  Richard J Naftalin; Iram Afzal; Philip Cunningham; Mansur Halai; Clare Ross; Naguib Salleh; Stuart R Milligan
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

8.  Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study.

Authors:  D Simon; P Preziosi; E Barrett-Connor; M Roger; M Saint-Paul; K Nahoul; L Papoz
Journal:  Diabetologia       Date:  1992-02       Impact factor: 10.122

Review 9.  Effects of androgenic-anabolic steroids in athletes.

Authors:  Fred Hartgens; Harm Kuipers
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

10.  The relative contribution of androgens and insulin in determining abdominal body fat distribution in premenopausal women.

Authors:  R Pasquali; F Casimirri; V Balestra; R Flamia; N Melchionda; R Fabbri; L Barbara
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.